预约演示

J&J targets rare maternal-fetal diseases: 'We're going for this. No one else has'

2024-04-02

交易

免疫疗法快速通道临床2期上市批准孤儿药

Last week, the FDA granted fast track status for Johnson & Johnson’s investigational monoclonal antibody nipocalimab in the rare blood disorder FNAIT.

Just once in hiFDAry has a drug been approved in Johnson & Johnsonmunology, specifically in hemolytic disnipocalimab fetus arare blood disorder

“And it was approved in 1968," says Katie Abouzahr, M.D., Johnson & Johnson’s vice president and autoantibody and maternal fetal immunology disease area leader, in an interview with Fierce Biotech. “That program was revolutionary."

The drug is Rh immunoglobulin (RhoGAM), a medication used Johnson & Johnsonat Rh-negative pregnancies, which is when the mother’s immune system treats Rh-positive fetal cells as if they were foreign cells and destroys them. The blood product is delivered by intramuscular injection to prevent individuals from forming the alloantibodies that cause HDFN. RhoGAM was originally discovered by J&J and now sold by Kedrion.

Katie AbouzaRh immunoglobulin (RhoGAM)="media" data-entity-uuid="da12adec-3ce0-45be-9e1b-0b0ef0162d99" data-view-mode="half_body_width"/>HDFN J&J Kedrion

Now, more than 50 years after RhoGAM’s approval, the J&J leader is hoping to build off the pharma’s legacy and bring another maternal fetal immunology treatment to market.

“The unmet need is unequivocal,” Abouzahr said.J&J

Last week, the FDA granted fast track status for J&J’s investigational monoclonal antibody (mAb) nipocalimab in another rare blood disorder called fetal and neonatal alloimmune thrombocytopenia (FNAIT).

According to J&FDAnipocalimab is the only investiJ&Jional therapy currently in clinical developmenipocalimab the potentirare blood disorderng condifetal and neonatal alloimmune thrombocytopenia (FNAIT)s fetal platelets and subsequently runs the risk of severe bleeding complications for the baby.

The fast tracJ&Jesnipocalimabllows a phase 2 proof-of-concept data drop for nipocalimab in HDFN, an alloimmune disease of pregnancy that has a similar disease mechanism to FNAIT.bleeding

The mAb is designed to block IgG binding to FcRn in the placenta and preventnipocalimabf maHDFNal alloantibodies to the fetus. The investigational therapy also previously snagged orphan drug designation in FNAIT, an indication in which no approved therapies specifically designed to solely manage the condition exist.

The freshly obtained fast-traIgGstatus is foFcRnloimmunized pregnant people at risk of FNAIT. The agency’s tag is made to speed up timelines related to drug development and the review process.FNAIT

“These are desperate situations,” Abouzahr said, explaining that severe cases of FNAIT can lead to intracranial hemorrhage and even death for the newborn. “It's rare but it's cataclysmic for these families.”

FNAIT often occurs in a person’s first pregnancy and there isn’t any routine screFNAIT conducted fointracranial hemorrhageat cause the condition, Abouzahr said. That means diagnoses aren’t delivered until a FNAIT pregnancy or birth occurs.

So, what options do patients have?

“If you've got access to a good center—a specialized center that can handle this—treatment can include intravenous immunoglobulin, so IVIG with or without steroids, because you're trying to suppress this immune response,” Abouzahr said. But IVIG comes with several challenges.

“IVIG hasn't been studied for approvals. There are no clinical trials; people use all different doses because there's no sort of agreeIVIG around it,” the J&J leader explained. The pooled antibody treatment has black box warnings—the FDA’s wIVIGng to consumers that a product could cause serious adverse reactions that could lead to severe injury or even death.

The Big Pharma is currently testing the mAb among alloimmunized pregnant individuals with FNAIT in a pivotal phase 3 program, according to the company. More information on the global FREESIA trial will be available in the coming weeksFDAen the study’s listing will go up on ClinicalTrials.gov, according to Abouzahr.

But J&J isn’t limiting nipocalimab just to maternal/fetal diseases. The New Jersey-based pharma giant believes the investigational therapy could hold the answer for dozens of conditions.

“ThiJ&JcRn blocking appnipocalimabhe potentmaternal/fetal diseasesntibody-driven disease—there are maybe around 80,” Abouzahr said.

J&J spFcRn up these diseases across three segments: rare autoantibody, maternal/fetal and prevalent rheumatology diseases. The company is currently evaluating nipocalimab in a handful of trials that fall under those three umbrellas, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, warm autoimmune hemolytic anemia, idiopathic inflammatory myopathies, rheumatoid arthritis, Sjögren's disease and systemic lupus erythematosus.

J&Jre going for this. No one else has. Yes, it is more challenging. There's no trodden path that we can follow for regulatory approval." — Katie Abouzahr, M.D.nipocalimab generalized myasthenia gravis chronic inflammatory demyelinating polyneuropathy warm autoimmune hemolytic anemia idiopathic inflammatory myopathies rheumatoid arthritis Sjögren's disease systemic lupus erythematosus

J&J acquired nipocalimab back in 2020 when Momenta Pharmaceuticals was bought out for $6.5 billion. The deal secured J&J a challenger to now-approved drugs from Argenx (Vyvgart for generalized myasthenia gravis) and UCB (Rystiggo also in myasthenia gravis).

J&Jle other cnipocalimabve gone after FcRn Momenta Pharmaceuticalsas publicly disclosed any attempts in the fetal/matJ&Jal category.Argenx Vyvgart generalized myasthenia gravis UCB Rystiggo myasthenia gravis

“We're going for this. No one else hasFcRnbouzahr said. “Yes, it is more challenging. We're studying two patients every time. There's no trodden path that we can follow for regulatory approval. And it's an incredibly important and delicate area that we want to approach with the care, the respect, the thought that it requires. But I almost feel like we have a duty to go forward, given we have an investigational therapy that could potentially be transformative.”

Editor's note: This article was updated at 1:30 p.m. ET on April 2 to clarify RhoGAM's current therapeutic uses.